Upgrade to SI Premium - Free Trial

Stifel on Summit Therapeutics plc (SMMT): 'first look, ever, at an emerging OS from an invonescimab P3 randomized against antiPD-1 (tislelizumab)'

April 21, 2026 12:33 PM
Stifel analyst Dara Azar reiterated a Buy rating and $45.00 price target on Summit Therapeutics plc (NASDAQ: SMMT)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments